Suchergebnisse - "Curtin, Nicola"

PubPharm (22)

1

PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS

enthalten in: NMR in biomedicine | 2017

von Almeida, G. | Bawn, C. | Galler, M. | +6

2

Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2017

von McCormick, A. | Donoghue, P. | Dixon, M. | +6

3

Strategies Employed for the Development of PARP Inhibitors

enthalten in: Methods in molecular biology (Clifton, N.J.) | 2017

von Canan, S. | Maegley, K. | Curtin, N.

4

Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2016

von O'Donnell, R. | Kaufmann, A. | Woodhouse, L. | +4

5

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

enthalten in: British journal of cancer | 2016

von Drew, Y. | Ledermann, J. | Hall, G. | +14

CommentIn: Br J Cancer. 2016 Mar 29;114(7):713-5. - PMID 27022824

6

Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer

enthalten in: Molecular oncology | 2016

von Alsubhi, N. | Middleton, F. | Abdel-Fatah, T. | +12

7

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

enthalten in: Molecular cancer therapeutics | 2015

von Parrish, K. | Cen, L. | Murray, J. | +11

8

PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib

enthalten in: Clinical pharmacology in drug development | 2015

von Wang, D. | Li, C. | Sun, W. | +7

9

Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself

enthalten in: PloS one | 2015

von McCrudden, C. | O'Rourke, M. | Cherry, K. | +14

10

The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis

enthalten in: PloS one | 2014

von O Donnell, R. | McCormick, A. | Mukhopadhyay, A. | +9